

Supplementary Table SII Associations between non-imputed urinary paracetamol, *p*-aminophenol and TTP.

	Partner-specific models			Couple-based models		
	Unadjusted FOR (95% CI)	Adjusted ^a FOR (95% CI)	Adjusted ^b FOR (95% CI)	Unadjusted ^c FOR (95% CI)	Adjusted ^d FOR (95% CI)	Adjusted ^e FOR (95% CI)
Females						
Paracetamol ^f	0.99 (0.95, 1.03)	1.02 (0.98, 1.06)	1.02 (0.98, 1.07)	1.00 (0.96, 1.04)	1.02 (0.97, 1.07)	1.02 (0.98, 1.07)
Quartile 1	—	—	—	—	—	—
Quartile 2	1.19 (0.85, 1.65)	1.27 (0.88, 1.83)	1.30 (0.90, 1.88)	1.29 (0.91, 1.81)	1.48 (0.99, 2.21)	1.54 (1.03, 2.31)
Quartile 3	1.17 (0.84, 1.65)	1.46 (1.00, 2.14)	1.49 (1.02, 2.19)	1.23 (0.86, 1.75)	1.56 (1.02, 2.36)	1.59 (1.04, 2.40)
Quartile 4	1.03 (0.74, 1.45)	1.28 (0.87, 1.88)	1.38 (0.93, 2.05)	1.20 (0.84, 1.72)	1.51 (0.98, 2.30)	1.62 (1.05, 2.51)
<i>P</i> -trend	0.89	0.16	0.08	0.13	0.06	0.04
<i>p</i> -aminophenol ^f	0.95 (0.86, 1.04)	1.01 (0.90, 1.14)	1.00 (0.89, 1.13)	0.96 (0.87, 1.07)	1.05 (0.92, 1.20)	1.04 (0.91, 1.19)
Quartile 1	—	—	—	—	—	—
Quartile 2	1.21 (0.87, 1.68)	1.37 (0.94, 1.99)	1.35 (0.92, 1.97)	1.13 (0.80, 1.59)	1.36 (0.90, 2.06)	1.34 (0.88, 2.04)
Quartile 3	1.36 (0.98, 1.88)	1.40 (0.95, 2.06)	1.38 (0.94, 2.04)	1.34 (0.95, 1.89)	1.40 (0.93, 2.13)	1.39 (0.91, 2.12)
Quartile 4	0.76 (0.54, 1.07)	1.00 (0.66, 1.52)	0.96 (0.63, 1.46)	0.78 (0.54, 1.12)	1.13 (0.72, 1.78)	1.07 (0.68, 1.69)
<i>P</i> -trend	0.21	0.98	0.87	0.35	0.64	0.78
Summary measure ^f	0.99 (0.95, 1.02)	1.02 (0.98, 1.06)	1.02 (0.98, 1.06)	0.99 (0.96, 1.03)	1.02 (0.98, 1.06)	1.02 (0.99, 1.07)
Quartile 1	—	—	—	—	—	—
Quartile 2	0.99 (0.71, 1.37)	1.22 (0.84, 1.78)	1.25 (0.85, 1.82)	0.94 (0.67, 1.34)	1.16 (0.76, 1.76)	1.13 (0.74, 1.73)
Quartile 3	1.13 (0.81, 1.57)	1.39 (0.94, 2.05)	1.39 (0.94, 2.06)	1.21 (0.86, 1.70)	1.59 (1.04, 2.42)	1.60 (1.04, 2.45)
Quartile 4	0.74 (0.52, 1.03)	0.98 (0.65, 1.48)	1.00 (0.66, 1.51)	0.77 (0.54, 1.10)	1.00 (0.63, 1.58)	0.98 (0.73, 1.64)
<i>P</i> -trend	0.15	0.96	0.90	0.35	0.72	0.69
Males						
Paracetamol ^c	0.96 (0.92, 1.00)	0.95 (0.90, 0.99)	0.94 (0.90, 0.99)	0.95 (0.91, 1.00)	0.94 (0.89, 0.99)	0.94 (0.89, 0.99)
Quartile 1	—	—	—	—	—	—
Quartile 2	0.85 (0.61, 1.20)	0.87 (0.60, 1.26)	0.86 (0.59, 1.24)	0.81 (0.57, 1.14)	0.91 (0.61, 1.36)	0.91 (0.61, 1.37)
Quartile 3	0.98 (0.70, 1.38)	0.91 (0.62, 1.34)	0.93 (0.63, 1.36)	0.93 (0.65, 1.32)	0.92 (0.61, 1.39)	0.93 (0.62, 1.42)
Quartile 4	0.69 (0.48, 0.97)	0.69 (0.47, 1.02)	0.68 (0.46, 1.00)	0.64 (0.44, 0.92)	0.63 (0.41, 0.97)	0.63 (0.41, 0.97)
<i>P</i> -trend	0.08	0.09	0.08	0.04	0.03	0.03
<i>p</i> -aminophenol ^c	0.92 (0.81, 1.03)	0.91 (0.78, 1.05)	0.91 (0.79, 1.06)	0.93 (0.82, 1.05)	0.91 (0.77, 1.07)	0.91 (0.78, 1.07)
Quartile 1	—	—	—	—	—	—
Quartile 2	0.90 (0.64, 1.28)	0.97 (0.66, 1.43)	0.97 (0.66, 1.43)	0.90 (0.61, 1.28)	0.94 (0.62, 1.41)	0.96 (0.63, 1.46)
Quartile 3	0.99 (0.70, 1.39)	1.20 (0.81, 1.79)	1.21 (0.81, 1.80)	1.01 (0.72, 1.45)	1.18 (0.77, 1.81)	1.18 (0.76, 1.81)
Quartile 4	0.84 (0.60, 1.18)	0.76 (0.51, 1.14)	0.79 (0.53, 1.18)	0.89 (0.62, 1.27)	0.81 (0.52, 1.26)	0.84 (0.54, 1.31)
<i>P</i> -trend	0.42	0.27	0.35	0.7	0.52	0.61
Summary measure ^{f,g}						
Quartile 1	0.95 (0.92, 0.99)	0.94 (0.90, 0.98)	0.94 (0.90, 0.98)	0.95 (0.92, 0.99)	0.94 (0.89, 0.98)	0.94 (0.89, 0.98)
Quartile 2	—	—	—	—	—	—
Quartile 3	1.11 (0.79, 1.56)	1.15 (0.79, 1.67)	1.14 (0.78, 1.67)	1.10 (0.78, 1.55)	1.11 (0.75, 1.66)	1.10 (0.73, 1.64)
Quartile 4	1.12 (0.79, 1.58)	1.27 (0.85, 1.89)	1.31 (0.87, 1.96)	1.19 (0.84, 1.69)	1.33 (0.87, 2.02)	1.35 (0.88, 2.07)
Quartile 1	0.74 (0.52, 1.05)	0.66 (0.43, 0.99)	0.66 (0.44, 1.01)	0.75 (0.53, 1.08)	0.66 (0.42, 1.02)	0.67 (0.43, 1.05)
<i>P</i> -trend	0.10	0.05*	0.06	0.18	0.09	0.14

P-trend from Wald test for nonlinearity; **P*-value <0.05 prior to rounding.

^aModels were adjusted for age, BMI, creatinine, smoking status (cotinine dichotomized at a threshold of 10 ng/ml), race/ethnicity (dichotomized, non-White versus White) and income (dichotomized at \$70 000).

^bModels included covariates in model a and hypertension and hypothyroidism.

^cModels included concentration for paracetamol or *p*-aminophenol and partner's concentration as well.

^dModels were adjusted for female age, female and male age difference, female and male BMI, creatinine, smoking status (cotinine dichotomized at a threshold of 10 ng/ml), race/ethnicity (dichotomized, non-White versus White) and income (dichotomized at \$70 000).

^eModels were adjusted for covariates listed in model C along with female and male hypertension and hypothyroid.

^fModeled as continuous variable.

^gSummary measure of urinary paracetamol and metabolite *p*-aminophenol.